Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

Ortega, Héctor; Meyer, Erik; Brusselle, Guy; Asano, Koichiro; Price, R. G.; Prazma, Charlene M.; Albers, FC; Yancey, Steve; Gleich, Gerald J.

doi:10.1055/s-0039-1678313

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reasons of a no response to a biological treatment can be identified: i) no correct phenotype assessment at baseline; ii) clinical impact of concomitant comorbidities; iii) incomplete capacity of the biological drug to abrogate the airway process; iv) long-term history of asthma diseases with irreversible histological and functional consequences (airways remodeling; fixed airflow obstruction); v) no adherence to biological treatment (patient in home therapy); vi) development of neutralizing anti-drug antibodies (Table 1) [121][122][123][124][125]. In fact, biologicals, including mAbs, are structurally immunogenic, and the formation of antibodies [anti-drug antibodies (ADA)].…”

Section: Patients Non Responding To Biologicsmentioning

confidence: 99%

Severe Asthma and Biologics: Managing Complex Patients

Matucci¹,

Micheletto²,

Vultaggio³

2023

J Investig Allergol Clin

View full text Add to dashboard Cite

Bronchial asthma is a chronic airway inflammatory disease of the respiratory tract that varies in terms of clinical presentations (phenotypes) and distinct underling pathophysiological mechanisms (endotypes). The definition of phenotype/endotype is crucial tak-ing into account the availability of novel biologic agent dedicated to patients who do not respond to conventional therapies. Although patients suffering from type 2 severe asthma significantly benefit from treatment with biologics no responders patients have been identified. Comorbidities increase the symptoms of asthma and complicate the overall management of the disease. The assessment and treatment of comorbidities is a crucial step and they the appropriate management may improve asthma symptoms and morbidity. Among comorbidities certainly chronic rhinosinusit with nasal polyps, obesity, bronchiectasis and immune defects represent a group of clinical conditions that negatively impact on asthma control despite a correct treatment. Although asthma is frequently characterized by an increase of blood eosinophils that releasing mediators and cytokines are involved in the inflammatory processes of airways wall, in patients with very high blood eosinophil levels it is opportune to be very careful in discerning whether it is a case of isolated severe eosinophilic asthma or a case of asthma in EGPA disease. In addition, hypereosinophilia can be the consequence of specific biological treatment as in the case of dupilumab. In this paper we have outlined the clinical features of those patients with severe asthma in which the management of the disease can be more complex.

show abstract

Section: Patients Non Responding To Biologicsmentioning

confidence: 99%

Severe Asthma and Biologics: Managing Complex Patients

Matucci¹,

Micheletto²,

Vultaggio³

2023

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…O rtega et al. [26] have looked at the immunogenicity profile of mepolizumab during the Phase III clinical development programme in severe asthma (COSMOS and COLUMBA). There was no correlation between anti-drug antibody titres and change in BECs.…”

Section: Asthmamentioning

confidence: 99%

Research highlights from the 2018 European Respiratory Society International Congress: airway disease

et al. 2019

View full text Add to dashboard Cite

The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses only some of the high-quality research studies presented at this year's Congress, with a particular focus on airway diseases including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and cough, as presented through Assembly 5 of the ERS (Airway Diseases: Asthma and COPD). The authors establish the key take-home messages of these studies, compare their findings and place them in the context of current understanding.

show abstract

“…The efficacy and safety of biologics can potentially be hampered by auto-immune responses against these biological agents (6). Data presented at the ERS from over 1,300 patients across five phase III studies of mepolizumab where anti-drug antibodies and neutralizing antibodies were measured at multiple time points, indicated that the agent was well tolerated with minimal potential to mount antidrug antibodies (7).…”

Section: Update On Asthmamentioning

confidence: 99%